Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China; Department of Gastroenterology, No. 463 Hospital of Chinese People's Liberation Army, Shenyang, China.
Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China.
Clin Gastroenterol Hepatol. 2014 Nov;12(11):1801-12.e7. doi: 10.1016/j.cgh.2014.04.026. Epub 2014 Apr 30.
BACKGROUND & AIMS: We conducted a systematic review and meta-analysis to evaluate the associations of the coagulation factor V (encoded by F5) Leiden (FVL) or prothrombin (encoded by F2) G20210A mutation with Budd-Chiari syndrome or portal vein thrombosis (PVT).
Relevant articles were identified in searches of the PubMed, EMBASE, Cochrane Library, and ScienceDirect databases. The prevalence of the FVL and prothrombin G20210A mutations were compared between patients with Budd-Chiari syndrome or PVT without cirrhosis and healthy individuals (controls) and between patients with cirrhosis, with and without PVT. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated.
We initially identified 869 articles, and included 27 in our final analysis. Compared with controls, patients with Budd-Chiari syndrome had a significantly higher prevalence of the FVL mutation (OR, 6.21; 95% CI, 3.93-9.79) and a similar prevalence of the prothrombin G20210A mutation (OR, 1.90; 95% CI, 0.69-5.23); patients with PVT without cirrhosis had a significantly higher prevalence of the FVL mutation (OR, 1.85; 95% CI, 1.09-3.13) or the prothrombin G20210A mutation (OR, 5.01; 95% CI, 3.03-8.30). Compared with patients with cirrhosis without PVT, patients with cirrhosis and PVT had a significantly higher prevalence of the FVL mutation (OR, 2.55; 95% CI, 1.29-5.07). We observed a trend toward a higher prevalence of the prothrombin G20210A mutation in patients with cirrhosis and PVT, but the difference was not statistically significant (OR, 2.93; 95% CI, 0.94-9.07).
Based on a meta-analysis, the FVL mutation is associated with an increased risk of Budd-Chiari syndrome, PVT without cirrhosis, and PVT in cirrhosis. The prothrombin G20210A mutation is associated with PVT, but not Budd-Chiari syndrome. Studies are needed to confirm these findings in different racial and ethnic groups.
我们进行了一项系统评价和荟萃分析,以评估凝血因子 V(由 F5 编码)莱顿(FVL)或凝血酶原(由 F2 编码)G20210A 突变与布加综合征或门静脉血栓形成(PVT)之间的关联。
在 PubMed、EMBASE、Cochrane 图书馆和 ScienceDirect 数据库中进行了相关文献检索。比较了布加综合征或无肝硬化 PVT 患者与健康对照者(对照组)之间、肝硬化患者与 PVT 患者之间的 FVL 和凝血酶原 G20210A 突变的发生率。计算了比值比(OR)及其 95%置信区间(CI)。
我们最初确定了 869 篇文章,并对其中 27 篇进行了最终分析。与对照组相比,布加综合征患者 FVL 突变的发生率显著更高(OR,6.21;95%CI,3.93-9.79),而凝血酶原 G20210A 突变的发生率相似(OR,1.90;95%CI,0.69-5.23);无肝硬化 PVT 患者的 FVL 突变(OR,1.85;95%CI,1.09-3.13)或凝血酶原 G20210A 突变(OR,5.01;95%CI,3.03-8.30)的发生率显著更高。与无 PVT 的肝硬化患者相比,合并 PVT 的肝硬化患者的 FVL 突变发生率显著更高(OR,2.55;95%CI,1.29-5.07)。我们观察到合并 PVT 的肝硬化患者中凝血酶原 G20210A 突变的发生率呈上升趋势,但差异无统计学意义(OR,2.93;95%CI,0.94-9.07)。
基于荟萃分析,FVL 突变与布加综合征、无肝硬化 PVT 和肝硬化合并 PVT 的风险增加相关。凝血酶原 G20210A 突变与 PVT 相关,但与布加综合征无关。需要在不同种族和民族群体中开展研究以证实这些发现。